Description of antipanic therapy in a prospective longitudinal study

Journal of Clinical Psychopharmacology

Volumn 16, Issue 3, 1996, Pages 223-232

  Yonkers, Kimberly A ^a   Ellison, James M ^b,c   Shera, David M ^d   Pratt, Lisa A ^e   Cole, Jonathan O ^f,g   Fierman, Eugene ^d   Keller, Martin B ^h   Lavori, Philip W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Harvard Pilgrim Health Care   (United States)

^d BROWN UNIVERSITY   (United States)

^e Harvard Medical School ^*

^f MCLEAN HOSPITAL   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BUSPIRONE; CHLORPROMAZINE; CLONAZEPAM; DESIPRAMINE; DIAZEPAM; DOXEPIN; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LOXAPINE; MESORIDAZINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; TIOTIXENE; TRANYLCYPROMINE; TRIFLUOPERAZINE; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID;

ADULT; AGORAPHOBIA; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY;

ADULT; ANTI-ANXIETY AGENTS; FEMALE; HOSPITALS, TEACHING; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES;

EID: 0029953542     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199606000-00006     Document Type: Article

References (59)

1. Keller MB, Lavori PW, Klerman GL, Andreasen NC, Endicott J, Coryell W, Fawcett J, Rice JP, Hirschfeld RMA. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986;43:458-66.
2. Sackheim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 1990;10:96-104.
3. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408.
4. Zitrin CM, Klein DF, Woerner MG, Ross DC. Treatment of phobias. Arch Gen Psychiatry 1983;40:125-38.
5. Liebowitz MR. Imipramine in the treatment of panic disorder and its complications. Psychiatr Clin North Am 1985;8:37-46.
6. Mavissakalian M, Perel M. Imipramine in the treatment of agoraphobia: dose-response relationship. Am J Psychiatry 1985;142:1032-6.
7. Gloger S, Grunhaus L, Birmacher B, Troudart T. Treatment of spontaneous panic attacks with clomipramine. Am J Psychiatry 1981;138:1215-7.
8. Grunhaus L, Gloger S, Birmacher B. Clomipramine treatment for panic attacks in patients with mitral valve prolapse. J Clin Psychiatry 1984;45:25-7.
9. Johnston DG, Troyer IE, Whitsett SF. Clomipramine treatment of agoraphobic women. Arch Gen Psychiatry 1988;45:453-9.
10. Lydiard RB. Desipramine in agoraphobia with panic attacks: an open, fixed-dose study. J Clin Psychopharmacol 1987;7:258-60.
11. Ballenger JC. Pharmacotherapy of the panic disorders. J Clin Psychiatry 1986;47:27-32.
12. Sheehan DV, Davidson J, Manschreck T, van wyck Fleet J. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 1983;3:28-31.
13. Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, Quadrino LM, Heninger GR. Drug treatment of panic disorder the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986;47:580-6.
14. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987;7:329-32.
15. Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, Klein DF. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-21.
16. den Boer JA, Westenberg HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1987;3:59-74.
17. Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321-6.
18. Tyrer P, Candy J, Kelly D. Phenelzine in phobic anxiety: a controlled trial. Psychol Med 1973;3:120-4.
19. Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987;48:55-9.
20. Sheehan D, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-9.
21. Chouinard G, Annable L, Fontaine R, Solyom L. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind, placebo-controlled study. Psychopharmacology 1982;77:229-33.
22. Liebowitz MR, Fyer A, Gorman A, Campeas R, Levin A, Davies SR, Goets D, Klein DF. Alprazolam in the treatment of panic disorders. J Clin Psychopharmacol 1986;6:13-20.
23. Schweizer E, Rickels K, Weiss S, Zavadonick S. Maintenance treatment of panic disorder. Arch Gen Psychiatry 1993;50:51-60.
24. Ballenger JC, Burrows GD, DuPont RL, Lesser IM, Noyes R, Pecknold JC, Rifkin A, Swinson RP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry 1988;45:413-22.
25. Lesser IM, Lydiard RB, Antal E, Rubin RT, Ballenger JC, DuPont R. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992;149:1556-62.
26. Uhlenhuth EH, Matuzas W, Glass RM, Easton C. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989;17:261-70.
27. Noyes RJ, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, Henrichs JV. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984;14:287-92.
28. Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986;47:458-60.
29. Schweizer E, Pohl R, Balon R, Fox F, Rickles K, Yeragani VK. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990;23:90-3.
30. Spier SA, Tesar GE, Rosenbaum JF, Woods SW. Treatment of panic disorder and agoraphobia with clonazepam. J Clin Psychiatry 1986;47:238-42.
31. Beaudry P, Fontaine R, Chouinard G, Annable L. Clonazepam in the treatment of patients with recurrent panic attacks. J Clin Psychiatry 1986;47:83-5.
32. Tesar GE, Rosenbaum JF, Pollack MH, Herman JB, Sachs GS, Mahoney EM, Cohen LS, McNamara M, Goldstein S. Clonazepam versus alprazolam in the treatment of panic disorder interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry 1987;48:16-9.
33. Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G, Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994;14:111-8.
34. McNair DM, Kahn RJ. Imipramine compared with a benzodiazepine for agoraphobia. In: Klein DF, Rabkin J, eds. Anxiety: new research and changing concepts. New York: Raven Press, 1981:69-80.
35. Munjack DJ, Rebal R, Shaner R, Staples F, Braun R, Leonard M. Imipramine versus propranolol for the treatment of panic attacks: a pilot study. Compr Psychiatry 1985;26:80-9.
36. Klein E, Uhde T. Controlled study of verapamil for treatment of panic disorder. Am J Psychiatry 1988;145:431-4.
37. Uhde TW, Sftein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988;145:1104-9.
38. Tyrer P, Steinberg D. Symptomatic treatment of agoraphobia and social phobias: a follow-up study. Am J Psychiatry 1975;127:163-8.
39. Pohl R, Balon R, Yeragani VK, Gershon S. Serotonergic anxiolytics in the treatment of panic disorder, a controlled study with buspirone. Psychopathology 1989;22:60-7.
40. Uhde TW, Stein MB, Vittone BJ. Behavioral and physiological effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry 1990;46:170-7.
41. Yonkers KA, Ellison SM, Shera DM, Pratt CA, Langford CM, Cole JO, White K, Lavori PW, Keller MB. Pharmacotherapy observed in a large prospective longitudinal study in anxiety disorders. Psychopharmacology 1992;28:131-7.
42. Hogarty G, Larkin BH, Hirschfeld RM. Personal history of depressive disorders. Available from Dr. Hirshfeld at University of Texas Medical Branch, Department of Psychiatry, Galveston, TX 77550.
43. Myers JK. Yale greater New Haven health survey. Available from Dr. Myers at Yale University, New Haven, CT 06520.
44. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey: reliability and validity in patient population. Med Care 1988;26:724-35.
45. Spitzer RL, Williams JB, Gibbon M, First MB. Structured clinical interview for DSM-III-R - patient version (SCID-P). Biometrics Research Department, New York State Psychiatric Institute, New York, NY 10032.
46. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia (SADS-L). Arch Gen Psychiatry 1978;35:837-44.
47. Keller MB, Lavori PW, Nielsen E. SCALUP (SCID-P plus SADS-L). Available from Dr. Keller, Butler Hospital, 345 Blackstone Blvd., Providence, RI 02906.
48. Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott NC, Andreasen NC. The longitudinal interval follow-up evaluation: a comprehensive method for assessing out-come in prospective longitudinal studies. Arch Gen Psychiatry 1987;44:540-8.
49. Perry JC, Stekee G, Goisman R, Massion A, Peterson LG. The psychosocial treatment interview. Available from Dr. Perry, Cambridge Hospital, 1493 Cambridge Street, Cambridge, MA 02139.
50. Ellison J, Yonkers K, Shera D, Pratt L. Side effect survey. Available from Dr. Ellison, Harvard Community Medical Center, Harvard Community Health Plan, 20 Wall St., Burlington, MA 01803.
51. Keller MB, Klerman GL, Lavori PW, Fawcwett JA, Coryell W, Endicott J. Treatment received by depressed patients. JAMA 1982;248:1848-55.
52. Statistical Analysis Software (SAS). SAS Institute, SAS Circle, Box 8000, Cary, NC 27512-8000.
53. Cox BJ, Endler NS, Lee PS, Swinson RP. A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. J Behav Ther Exp Psychiatry 1992;23:175-82.
54. Goisman R, Rogers M, Steketee G, Warshaw M, Cuneo P, Keller M. Utilization of behavioral methods in a multicenter anxiety disorders study. J Clin Psychiatry 1993;54:213-8.
55. Briggs AC, Stretch DD, Brandon S. Subtyping of panic disorder by symptom profile. Br J Psychiatry 1993;163:201-9.
56. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Sevrin B, Soegaard H, Calberg H, Judge R, Ohstrom JK, Manniche PM. Paroxetine in the treatment of panic disorders. Br J Psychiatry 1995;167:374-9.
57. Noyes R, Garvey MJ, Cook BL, Samuelson L. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989;50:163-9.
58. Eddy DM. Variations in physician practice: the role of uncertainty. Health Aff 1984;3:74-89.
59. Goldberg H, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1989;136:1184-7.